Alkem Laboratories Ltd banner

Alkem Laboratories Ltd
NSE:ALKEM

Watchlist Manager
Alkem Laboratories Ltd Logo
Alkem Laboratories Ltd
NSE:ALKEM
Watchlist
Price: 5 400 INR 1.05%
Market Cap: ₹645.6B

P/OCF

35.7
Current
16%
More Expensive
vs 3-y average of 30.7

Price to Operating Cash Flow (P/OCF) ratio compares a company`s market value to the cash it generates from its core operations.

P/OCF
35.7
=
Market Cap
₹667.6B
/
Operating Cash Flow
₹18.1B

Price to Operating Cash Flow (P/OCF) ratio compares a company`s market value to the cash it generates from its core operations.

P/OCF
35.7
=
Market Cap
₹667.6B
/
Operating Cash Flow
₹18.1B

Valuation Scenarios

Alkem Laboratories Ltd is trading above its 3-year average

If P/OCF returns to its 3-Year Average (30.7), the stock would be worth ₹4 647.91 (14% downside from current price).

Statistics
Positive Scenarios
0/4
Maximum Downside
-36%
Maximum Upside
No Upside Scenarios
Average Downside
20%
Scenario P/OCF Value Implied Price Upside/Downside
Current Multiple 35.7 ₹5 400
0%
3-Year Average 30.7 ₹4 647.91
-14%
5-Year Average 31.7 ₹4 796.73
-11%
Industry Average 29.2 ₹4 409.24
-18%
Country Average 23 ₹3 470.74
-36%

Forward P/OCF
Today’s price vs future operating cash flow

Not enough data available to calculate forward P/OCF

Peer Comparison

All Multiples
P/OCF
P/E
All Countries
Close
Market Cap P/OCF P/E
IN
Alkem Laboratories Ltd
NSE:ALKEM
639B INR 35.7 27.2
US
Eli Lilly and Co
NYSE:LLY
883B USD 52.5 42.8
US
Johnson & Johnson
NYSE:JNJ
553.5B USD 22.6 26.3
CH
Roche Holding AG
SIX:ROG
248.4B CHF 13.7 20.1
UK
AstraZeneca PLC
LSE:AZN
216.3B GBP 19.7 28
US
Merck & Co Inc
NYSE:MRK
270.2B USD 16.4 14.8
CH
Novartis AG
SIX:NOVN
216.3B CHF 14.6 20.7
IE
Endo International PLC
LSE:0Y5F
244.4B USD 907.7 -83.6
DK
Novo Nordisk A/S
CSE:NOVO B
1.1T DKK 10.1 11.8
US
Pfizer Inc
NYSE:PFE
151.8B USD 13 19.5
US
Bristol-Myers Squibb Co
NYSE:BMY
122B USD 8.6 17.3
P/E Multiple
Earnings Growth PEG
IN
Alkem Laboratories Ltd
NSE:ALKEM
Average P/E: 22.9
27.2
7%
3.9
US
Eli Lilly and Co
NYSE:LLY
42.8
32%
1.3
US
Johnson & Johnson
NYSE:JNJ
26.3
8%
3.3
CH
Roche Holding AG
SIX:ROG
20.1
14%
1.4
UK
AstraZeneca PLC
LSE:AZN
28
25%
1.1
US
Merck & Co Inc
NYSE:MRK
14.8
14%
1.1
CH
Novartis AG
SIX:NOVN
20.7
14%
1.5
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -83.6 N/A N/A
DK
Novo Nordisk A/S
CSE:NOVO B
11.8
0%
N/A
US
Pfizer Inc
NYSE:PFE
19.5
22%
0.9
US
Bristol-Myers Squibb Co
NYSE:BMY
17.3
16%
1.1

Market Distribution

In line with most companies in India
Percentile
66th
Based on 2 204 companies
66th percentile
35.7
Low
0.5 — 14
Typical Range
14 — 39.7
High
39.7 —
Distribution Statistics
India
Min 0.5
30th Percentile 14
Median 23
70th Percentile 39.7
Max 28 676

Alkem Laboratories Ltd
Glance View

Alkem Laboratories Ltd., founded in 1973, has emerged as a significant player in India's pharmaceutical landscape, deftly combining innovation with a robust distribution network. Anchored in Mumbai, Alkem began as a modest venture but quickly evolved into a powerhouse, renowned for manufacturing a broad spectrum of branded generics, over-the-counter products, and active pharmaceutical ingredients (APIs). The company's success lies in its ability to cater to both domestic and international markets, primarily thriving on the ever-increasing demand for affordable healthcare solutions. Its formidable market presence in India is supported by a strong sales force and an extensive distribution network, ensuring its therapies reach even the most remote corners of the country. Internationally, Alkem has carved a niche for itself, with the United States being one of its major export markets. It strategically entered this competitive arena, building a portfolio of ANDAs (Abbreviated New Drug Applications) that allowed it to provide lower-cost alternatives to big pharma's patented drugs. This not only fueled its revenue growth but also fortified its standing as a go-to source for quality generics. Alkem's research and development efforts underpin its commitment to healthcare innovation, as it constantly seeks to expand its therapeutic repertoire. By consistently focusing on quality, affordability, and resourceful adaptation to global healthcare needs, Alkem Laboratories Ltd. has managed to script a growth story that is both impressive and sustainable.

ALKEM Intrinsic Value
4 218.11 INR
Overvaluation 22%
Intrinsic Value
Price ₹5 400
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett